HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

Core Insights - HanchorBio and WuXi Biologics have signed a strategic collaboration agreement to develop and manufacture next-generation bi- and multi-functional fusion programs from HanchorBio's pipeline [1][3][4] Company Overview - HanchorBio is a global clinical-stage biotechnology company focused on advancing immunotherapies for oncology and autoimmune diseases, utilizing its proprietary Fc-Based Designer Biologics (FBDB™) platform [1][8][9] - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics development and manufacturing [10][11] Collaboration Details - Under the agreement, WuXi Biologics will offer integrated services including cell line development, process and bioassay development, drug product formulation, and GMP manufacturing to support HanchorBio's innovative fusion protein portfolio [3][4] - The partnership aims to enhance clinical translation, improve CMC execution efficiency, and support scalable global development and manufacturing [3][4] Strategic Goals - HanchorBio's strategy focuses on advancing its multi-asset pipelines with speed, robustness, and capital efficiency from early clinical stages to commercialization [4][6] - The collaboration is expected to shorten development timelines and maintain flexibility across multiple clinical programs [4][6] Expertise and Capabilities - WuXi Biologics has extensive experience in complex modalities, supporting 945 projects as of 2025, with approximately 60% involving bi- and multi-specific antibodies, ADCs, and fusion proteins [5][11] - The company utilizes proprietary technology platforms to enhance speed, quality, and scalability in biologics development [5][11] Future Outlook - The partnership represents a significant step for HanchorBio in aligning discovery innovation with industrial-scale execution, advancing its oncology and autoimmune pipelines toward global clinical development [6][7]